A Phase 1/2 First-In-Human Study Of BMS-986249 Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Phase 1/2 First-In-Human Study Of BMS-986288 Alone And In Combination With Nivolumab In Advanced Malignant Tumors Read more
A Phase 1/2 Study Of BMS-986340 As Monotherapy And In Combination With Nivolumab In Participants With Advanced Solid Tumors Read more
Phase 1 Study Of BMS-986416 (TGF-B Inhibitor) Alone And In Combination With Nivolumab In Advanced Malignant Tumors. Read more
A Multicenter, Open-Label Study With A Randomized Control Arm Of The Efficacy, Safety, And Pharmacokinetics Of Intravenously Infused Berubicin In Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure Of Standard First Line Therapy Read more
A Phase 1/2 Study Of Selinexor In Combination With Standard Of Care (Soc) Therapy For Actively Diagnosed Or Recurrent Glioblastoma Read more
EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma Read more
Open-Label, Multicenter, Phase 1 Study To Assess The Safety Of P BCMA-101 In Subjects With Relapsed / Refractory Multiple Myeloma (MM) Followed By A Phase 2 Assessment Of Response And Safety (PRIME) Read more
